We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

159 hedge funds and large institutions have $612M invested in Progenics Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 16

69% more call options, than puts

Call options by funds: $6.1M | Put options by funds: $3.62M

26% more funds holding

Funds holding: 126 → 159 (+33)

25% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 36

18% more capital invested

Capital invested by funds: $518M → $612M (+$93.5M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
159
Holders Change
+33
Holders Change %
+26.19%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
56
Increased
45
Reduced
36
Closed
16
Calls
$6.1M
Puts
$3.62M
Net Calls
+$2.48M
Net Calls Change
+$1.34M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$95M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
3
PWAM
Park West Asset Management
California
+$12.6M
4
Invesco
Invesco
Georgia
+$10.3M
5
Goldman Sachs
Goldman Sachs
New York
+$5.62M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$69.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.91M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$2.13M
4
RA
Royce & Associates
New York
-$2.08M
5
PFC
Phocas Financial Corp
California
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
51
Swiss National Bank
Switzerland
$1.09M – – –
VEA
52
Virtus ETF Advisers
New York
$1.09M +$111K +11,087 +11%
CCM
53
Cadence Capital Management
Massachusetts
$1.07M +$463K +46,365 +70%
BA
54
BKS Advisors
Michigan
$1.01M – – –
PPA
55
Parametric Portfolio Associates
Washington
$956K +$254K +25,413 +34%
Canada Life
56
Canada Life
Manitoba, Canada
$948K +$882K +88,358 +724%
ACP
57
Acuta Capital Partners
California
$944K +$998K +100,000 New
Fisher Asset Management
58
Fisher Asset Management
Washington
$922K +$186K +18,604 +24%
Citigroup
59
Citigroup
New York
$870K -$740K -74,188 -45%
Dimensional Fund Advisors
60
Dimensional Fund Advisors
Texas
$796K -$48.8K -4,887 -5%
VKH
61
Virtu KCG Holdings
New York
$749K +$305K +30,533 +63%
EI
62
EAM Investors
California
$735K +$778K +77,912 New
JP Morgan Chase
63
JP Morgan Chase
New York
$726K +$768K +76,925 New
SO
64
STRS Ohio
Ohio
$697K -$119K -11,900 -14%
State Board of Administration of Florida Retirement System
65
State Board of Administration of Florida Retirement System
Florida
$672K – – –
HK
66
Horizon Kinetics
New York
$635K +$599 +60 +0.1%
State of Tennessee, Department of Treasury
67
State of Tennessee, Department of Treasury
Tennessee
$618K +$654K +65,505 New
Barclays
68
Barclays
United Kingdom
$610K +$253K +25,305 +64%
Comerica Bank
69
Comerica Bank
Texas
$597K +$772K +77,316 New
AA
70
ALPS Advisors
Colorado
$569K -$70.4K -7,054 -10%
Manulife (Manufacturers Life Insurance)
71
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$555K +$240K +24,009 +69%
Squarepoint
72
Squarepoint
New York
$513K +$137K +13,740 +34%
SCM
73
Stevens Capital Management
Pennsylvania
$505K +$534K +53,540 New
CHAM
74
Clear Harbor Asset Management
Connecticut
$497K – – –
SC
75
Searle & Co
Connecticut
$481K +$509K +51,000 New
1 2
3
4 5

PGNX Hedge Fund Activity: Q1 2017 in Review

159 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2017, worth a combined $612M — up 18% from $518M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new PGNX positions and 16 closed out — a net gain of 40 holders — while 45 added to existing stakes and 36 trimmed.

The largest buyer was BlackRock, adding an estimated $95M. The largest seller was Broadfin Capital, cutting an estimated $69.4M.

  • 159 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2017, up from 126 in Q4 2016.
  • Funds reported $612M of Progenics Pharmaceuticals Inc stock for Q1 2017, up 18% quarter-over-quarter.
  • 56 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2017 and 16 closed out, a net change of +40 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $95M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q1 2017 was Broadfin Capital, an estimated $69.4M sold.

Based on aggregated 13F filings for Q1 2017.